In a groundbreaking study published in Nature Medicine, researchers have reclassified individuals carrying two copies of the APOE4 gene variant as virtually guaranteed to develop Alzheimer's disease, often at an earlier age. This revelation could revolutionize Alzheimer's research, diagnosis, and treatment strategies, marking carriers of the APOE4 gene as possessing a unique genetic form of the debilitating condition. Sterling Johnson, co-author of the study from the University of Wisconsin's Alzheimer's Disease Research Center, emphasized the significance of this discovery, suggesting that it may represent a genetic disease rather than just a risk factor indication.
For over three decades, scientists have recognized the heightened risk of Alzheimer's in individuals with two copies of the APOE4 gene variant compared to those with the more common APOE3 gene. Approximately 2% to 3% of the general population, or 15% of Alzheimer's patients, carry two copies of the APOE4 variant. The recent study by Dr. Juan Fortea and colleagues, which analyzed data from over 3,000 donated brains and 10,000 individuals from multiple countries, revealed compelling evidence that these double APOE4 carriers face an almost certain progression towards Alzheimer's, manifesting early-onset symptoms.
By the age of 65, the study found that at least 95% of individuals with two copies of APOE4 displayed abnormal levels of beta-amyloid, a protein associated with Alzheimer's, in their spinal fluid. Additionally, 75% showed positive brain scans for amyloid. These findings suggest a clear pattern of Alzheimer's biology among APOE4 homozygotes, meeting the criteria for a distinct genetic form of the disease characterized by predictable clinical and biological changes.
While some experts remain cautious about this reclassification, citing the similarity in underlying disease processes across various forms of Alzheimer's, the implications for treatment and care are significant. Patients with two copies of the APOE4 variant are at higher risk of adverse effects from certain treatments, such as brain bleeding and swelling, as observed in trials for Alzheimer's drug Leqembi. Consequently, the need to identify and enroll these individuals in preventive trials at an earlier age has been underscored.
As the research progresses, the findings could shape how disease risk is evaluated, drive advancements in clinical trials, and influence the development of targeted treatments for Alzheimer's. This new designation for Alzheimer's, particularly in relation to late-onset forms, could pave the way for a more personalized and effective approach to managing the condition. While further research is necessary, particularly among diverse populations, the study sets a crucial foundation for understanding and addressing Alzheimer's disease in those with a heightened genetic predisposition.